Market closed

Alkermes/$ALKS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Ticker

$ALKS
Trading on

Industry

Biotechnology

Headquarters

Dublin, Ireland

Employees

2,100

Alkermes Metrics

BasicAdvanced
$4.7B
Market cap
14.61
P/E ratio
$1.97
EPS
0.42
Beta
-
Dividend rate
$4.7B
0.42
$32.88
$22.22
1.8M
3.489
2.861
27.618
28.326
13.28%
8.98%
29.23%
14.609
3.191
3.6
3.85
15.235
-5.37%
55.25%
10.05%
50.99%

What the Analysts think about Alkermes

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Alkermes stock.

Alkermes Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Alkermes Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALKS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Alkermes stock?

Alkermes (ALKS) has a market cap of $4.7B as of November 24, 2024.

What is the P/E ratio for Alkermes stock?

The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 14.61 as of November 24, 2024.

Does Alkermes stock pay dividends?

No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of November 24, 2024.

When is the next Alkermes dividend payment date?

Alkermes (ALKS) stock does not pay dividends to its shareholders.

What is the beta indicator for Alkermes?

Alkermes (ALKS) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.